[Anti-HBs titers after a vaccination program in children and adolescents. Should a booster dose be given?].
OBJECTIVE
To determine the efficacy and immunogenicity achieved 6 years after the start of a massive vaccination campaign against hepatitis B in newborn infants and adolescents (12 years). The persistence of anti-hepatitis B virus surface antigen (HBS) levels and the need for a booster dose were also assessed.


METHODS
From 1993 to 1997 the Engerix vaccine (10 micrograms) and since then the Recombivax vaccine (5 micrograms). The vaccination schedule was the standard of three doses (0, 1, 6). Blood analyses were used for determination of anti-HBs between October of 1998 and May of 2000.


RESULTS
We studied 382 cases. Five years after the first dose, 96.1% (73/76) has anti-HBs and in 75% (57/76) levels were above 10UI/L. Six to seven years after vaccination anti-HBs were detected in 94,1 (32/34) of the children and in 70.6% (24/34) of these, levels were above 10UI/L.


CONCLUSIONS
A high percentage of children were found to have good levels of anti-HBs 67 years after vaccination. Recent studies show that booster doses are not required because of the immunologic memory that produces the vaccine. The anti-HB protective level (> or = 10UI/l) should not be taken into consideration because this level is only valid when passive immunity with immunoglobulins is applied.
García Llop
L
L
Centro de Salud de Manises. Valencia. lugallo@retemail.es
Asensi Alcoverro
A
A
Coll Más
P
P
Ramada Benedito
M A
MA
Grafiá Juan
C
C
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D006510:Hepatitis B Antibodies / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D017589:Immunization Programs; D007117:Immunization, Secondary; D007223:Infant; D007231:Infant, Newborn
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines